GLYCAN CHARACTERIZATION
Glycosylation is a key post-translational modification that significantly influences the bioactivity, stability, and immunogenicity of therapeutic glycoproteins. Unlike gene transcription, glycosylation is a non-template-driven process, resulting in high variability.
Given its profound impact on drug safety and performance, regulatory authorities classify glycosylation as a Critical Quality Attribute (CQA).
This makes its monitoring and control essential across every stage of drug development and manufacturing.
From early discovery to final formulation, we offer kits for the Release, Purification, Enrichment, and Labelling of monosaccharides, sialic acids, N- and O-glycans, as well as (Ultra) High-Performance Liquid Chromatography (u)HPLC columns and buffers
| Endoglycosidases | Exoglycosidases |
| Chemical Release | |
| Post-Release Clean Up | Post-Labelling Clean Up |
| Vacuum Manifold Accessories | |
| Traditional Labelling Kits | Ludger Velocity Labelling Kit | Glycopeptide Analysis |
| Sialic Acid Profiling | Monosaccharide Analysis | |
| LudgerSep N Amide Columns | LudgerSep R Reverse Columns |
| LudgerSep C Anion Columns | LudgerSep Buffers |
| N-Glycan - 2-AA Labelled | N-Glycan - 2-AB Labelled | N-Glycan - APTS Labelled |
| N-Glycan - Procainamide Labelled | N-Glycan - Unlabelled | O-Glycan Standards |
| Glycoprotein & Glycopeptide | Glycan Libraries | Quantitative Glycan Standards |
| Sialic Acid Standards | Glucose Homopolymer Ladder | Alpha-Gal Standards |
Key Features
- Critical Modification - Glycosylation affects bioactivity, stability, and immunogenicity of therapeutic proteins.
- High Variability - As a non-template-driven process, it introduces structural heterogeneity.
- Regulatory Importance - Classified as a Critical Quality Attribute (CQA) by regulatory authorities.
- Essential Monitoring - Must be controlled throughout drug development and manufacturing.
- Comprehensive Solutions - Kits available for glycan release, purification, labeling, and (u)HPLC analysis.
